This is a review from Indeed regarding a recent position for Lumos.
Looks like a temporary fill for the expansion of Viradx and Febridx in the US. Means the costings for the increase in team was only a short 3 month period, so we could assume next quarterly, that the outlay for expansion wont be there in the new quarterly. But product may remain selling, so a reduction in cost, and steady inflow of product sales.
LDX Chart, page-1594
-
- There are more pages in this discussion • 397 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
